ROCKVILLE, Md., March 10,
2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced new interim biomarker data from the Phase I/II
portion of the AFFINITY DUCHENNE® trial of RGX-202 for
the treatment of Duchenne muscular dystrophy will be presented at
the 2025 Muscular Dystrophy Association (MDA) Clinical &
Scientific Conference, taking place in Dallas, TX, March
16-19, 2025.
Title: RGX-202, an investigational gene therapy for the
treatment of Duchenne Muscular Dystrophy: Interim clinical data
(O75)
Session: Clinical Trials
Date/Time: Wednesday, March 19,
2025; 8:15 a.m.
CT
Presenter: Carolina
Tesi Rocha, M.D., Clinical
Professor, Neurology, Stanford
School of Medicine, Stanford Children's Health
Title: Enhanced therapeutic potential of a
microdystrophin with an extended C-terminal domain (P143)
Session: Pre-Clinical Research
Presenter: Steven Foltz,
Ph.D., Senior Scientist, Research & Early Development
at REGENXBIO
The presentations will be available in the Publications section
of REGENXBIO's website.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. Since its founding
in 2009, REGENXBIO has pioneered the development of AAV
Therapeutics, an innovative class of gene therapy
medicines. REGENXBIO is advancing a pipeline of AAV
Therapeutics for rare and retinal diseases, including RGX-202 for
the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet
AMD and diabetic retinopathy, being developed in collaboration with
AbbVie, and RGX-121 for the treatment of MPS II. Thousands of
patients have been treated with REGENXBIO's AAV
Therapeutic platform, including Novartis'
Zolgensma® for children with spinal muscular
atrophy. Designed to be one-time treatments, AAV Therapeutics have
the potential to change the way healthcare is delivered for
millions of people. For more information, please visit
WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--scientific-conference-302396530.html
SOURCE REGENXBIO Inc.
